Phase 2 Study of 153 Sm-EDTMP [samarium 153-SM lexidronam] Followed by Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases

Trial Profile

Phase 2 Study of 153 Sm-EDTMP [samarium 153-SM lexidronam] Followed by Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Samarium-153-SM-lexidronam (Primary)
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Sep 2010 Planned end date changed from 1 Mar 2010 to 1 Mar 2017 as reported by ClinicalTrials.gov.
    • 29 Sep 2008 Checked against clinicaltrials.gov record, added end date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top